clinical trial · NCT03845712
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
UCB BIOSCIENCES, Inc.·phase2·active not recruiting·n = 47
Thymidine Kinase 2 Deficiencydoxecitine and doxribtimine
brief summary
This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.
started
Jul 5, 2019
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
May 1, 2026
official title
A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol